"It's the genes, stupid". Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Life Science

• Publication date

  1995-05-19

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/0024-3205(95)00223-SPMID 7791516
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interactions of bupranolol with the polymorphic debrisoquine/sparteine monooxygenase (CYP2D6)

  2004cited by this paper
• Stereo- and regioselectivity of hepatic oxidation in man — Effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation

  2004cited by this paper
• The pharmacokinetics of indoramin and 6-hydroxyindoramin in poor and extensive hydroxylators of debrisoquine

  2004cited by this paper
• Progression of cervical intraepithelial neoplasia to cervical cancer: interactions of cytochrome P450 CYP2D6 EM and glutathione s-transferase GSTM1 null genotypes and cigarette smoking.

  1994cited by this paper
• Pharmacogenetic characteristics of the eosinophilia‐myalgia syndrome

  1994cited by this paper
• Cloning and sequencing of a new non-functional CYP2D6 allele: deletion of T1795 in exon 3 generates a premature stop codon.

  1994cited by this paper
• Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation.

  1994cited by this paper
• A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine

  1994cited by this paper
• The polymorphic cytochrome P-4502D6 is involved in the metabolism of both 5-hydroxytryptamine antagonists, tropisetron and ondansetron.

  1994cited by this paper
• Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine.

  1994cited by this paper
• CYP2D6 genotyping and the association with lung cancer susceptibility.

  1994cited by this paper
• Debrisoquin oxidation genotype and susceptibility to lung cancer

  1994cited by this paper
• Substrate-regulated, cAMP-dependent phosphorylation, denaturation, and degradation of glucocorticoid-inducible rat liver cytochrome P450 3A1.

  1994cited by this paper
• Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.

  1994cited by this paper
• Methodological issues in the interpretation of studies of the CYP2D6 genotype in relation to lung cancer risk.

  1994cited by this paper
• Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype.

  1994cited by this paper
• Debrisoquine hydroxylase gene polymorphism in familial Parkinson's disease.

  1994cited by this paper
• CYP2D6 phenotype determines the metabolic conversion of hydrocodone to hydromorphone

  1993cited by this paper
• Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism.

  1993cited by this paper
• Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites.

  1993cited by this paper
• CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.

  1993cited by this paper
• Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?

  1993cited by this paper
• Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes.

  1993cited by this paper
• A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease.

  1993cited by this paper
• Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.

  1993cited by this paper
• The pharmacogenetics of the selective serotonin reuptake inhibitors

  1993cited by this paper
• A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction

  1993cited by this paper
• The metabolism of aprindine in relation to the sparteine/debrisoquine polymorphism.

  1993cited by this paper
• Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6

  1993cited by this paper
• Relationship between personality and debrisoquine hydroxylation capacity

  1993cited by this paper
• Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease.

  1993cited by this paper
• PCR-based CYP2D6 genotyping for Finnish lung cancer patients.

  1993cited by this paper
• Inhibition by fluoxetine of cytochrome P450 2D6 activity

  1993cited by this paper
• Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms

  1993cited by this paper
• Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.

  1993cited by this paper
• A preliminary 3D model for cytochrome P450 2D6 constructed by homology model building

  1993cited by this paper
• Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.

  1992cited by this paper
• Metabolic cytochrome P450 genotypes and assessment of individual susceptibility to lung cancer.

  1992cited by this paper
• Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility.

  1992cited by this paper
• Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease.

  1992cited by this paper
• Ethylmorphine O‐deethylation cosegregates with the debrisoquin genetic metabolic polymorphism

  1992cited by this paper
• Genetic polymorphism of cytochromes P450: interethnic differences and relationship to incidence of lung cancer.

  1992cited by this paper
• The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification for the association of lung cancer and the debrisoquine metabolic phenotype.

  1992cited by this paper
• Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6.

  1992cited by this paper
• Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility.

  1992cited by this paper
• Mutant debrisoquine hydroxylation genes in Parkinson's disease.

  1992cited by this paper
• The relationship between paroxetine and the sparteine oxidation polymorphism

  1992cited by this paper
• Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.

  1991cited by this paper
• Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype.

  1991cited by this paper
• Deletion of the entire cytochrome P450 CYP2D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/sparteine polymorphism.

  1991cited by this paper
• Role of genetics and drug metabolism in human cancer risk.

  1991cited by this paper
• Role of P450IID6, the target of the sparteine‐debrisoquin oxidation polymorphism, in the metabolism of imipramine

  1991cited by this paper
• Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype

  1991cited by this paper
• Clinical Pharmacokinetics of Clomipramine

  1991cited by this paper
• Lack of a relationship between the polymorphism of debrisoquine oxidation and lung cancer.

  1991cited by this paper
• Debrisoquine oxidation in Parkinson's disease

  1991cited by this paper
• Debrisoquine oxidation phenotype and susceptibility to lung cancer.

  1990cited by this paper
• Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes.

  1990cited by this paper
• Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine

  1990cited by this paper
• Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification.

  1990cited by this paper
• Debrisoquine oxidation phenotype and susceptibility to lung cancer.

  1990cited by this paper
• The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins.

  1990cited by this paper
• The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene.

  1989cited by this paper
• Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in luman beings

  1989cited by this paper
• Debrisoquine hydroxylation polymorphism and personality.

  1989cited by this paper
• Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.

  1989cited by this paper
• In vitro characterization of the human cytochrome P‐450 involved in polymorphic oxidation of propafenone

  1989cited by this paper
• Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI).

  1988cited by this paper
• Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk.

  1988cited by this paper
• Human debrisoquine 4-hydroxylase (P450IID1): cDNA and deduced amino acid sequence and assignment of the CYP2D locus to chromosome 22.

  1988cited by this paper
• Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

  1988cited by this paper
• Interaction of fluoxetine with tricyclic antidepressants.

  1988cited by this paper
• Interaction of fluoxetine with tricyclic antidepressants.

  1988cited by this paper
• Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs.

  1988cited by this paper
• Is there a genetic factor in flecainide toxicity?

  1988cited by this paper
• First‐pass metabolism of imipramine and desipramine: Impact of the sparteine oxidation phenotype

  1988cited by this paper
• Pulse oximetry and methaemoglobinaemia.

  1988cited by this paper
• Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.

  1987cited by this paper
• Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment.

  1987cited by this paper
• Chromosomal assignment of human cytochrome P-450 (debrisoquine/sparteine type) to chromosome 22.

  1987cited by this paper
• P450 genes: evolution, regulation, and relationship to human cancer and pharmacogenetics.

  1986cited by this paper
• Plasma concentrations of nortriptyline and its 10-hydroxy metabolite in depressed patients--relationship to the debrisoquine hydroxylation metabolic ratio.

  1985cited by this paper
• Ecogenetics of Parkinson's disease: 4-hydroxylation of debrisoquine.

  1985cited by this paper
• Metabolism of methoxyphenamine in extensive and poor metabolizers of debrisoquin

  1985cited by this paper
• Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.

  1985cited by this paper
• Extremely rapid hydroxylation of debrisoquine: a case report with implication for treatment with nortriptyline and other tricyclic antidepressants.

  1985cited by this paper
• Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation

  1985cited by this paper
• Influence of genetic polymorphism on the metabolism and disposition of encainide in man.

  1984cited by this paper
• Quinidine‐induced rise in ajmaline plasma concentration

  1984cited by this paper
• Polymorphic hydroxylation of perhexiline maleate in man.

  1984cited by this paper
• Relationship of N‐demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism

  1984cited by this paper
• Dextromethorphan as a safe probe for debrisoquine hydroxylation polymorphism.

  1984cited by this paper
• Metabolic oxidation phenotypes as markers for susceptibility to lung cancer

  1984cited by this paper
• Polymorphic ability to metabolize propranolol alters 4‐hydroxypropranolol levels but not beta blockade

  1984cited by this paper
• Amitriptyline metabolism: Relationship to polymorphic debrisoquine hydroxylation

  1983cited by this paper
• Genetic polymorphism of phenformin 4‐hydroxylation

  1982cited by this paper
• HIGH PLASMA CONCENTRATIONS OF β-RECEPTOR BLOCKING DRUGS AND DEFICIENT DEBRISOQUINE HYDROXYLATION

  1982cited by this paper
• Defective metabolism of metoprolol in poor hydroxylators of debrisoquine.

  1982cited by this paper
• Polymorphic oxidation of sparteine and debrisoquine: Related pharmacogenetic entities

  1982cited by this paper
• Interindividual and interspecies variation in the metabolism of the hallucinogen 4-methoxyamphetamine.

  1979cited by this paper

• Enantioselective Quantification of Amphetamine and Metabolites in Serum Samples: Forensic Evaluation and Estimation of Consumption Time

  2021cites this paper
• Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder

  2020cites this paper
• Treatment of Painful Diabetic Neuropathy

  2020cites this paper
• Diabetic Neuropathy and Clinical Practice

  2020cites this paper
• Pharmacogenetics of neurological and psychiatric diseases at older age: has the time come?

  2017cites this paper
• Chapter 6 – Pharmacogenetics and Pharmacogenomics

  2017cites this paper
• Evolutionary genomics of genes involved in the environmental adaptation of metazoans

  2017cites this paper
• The pharmacogenetic road to avoid adverse drug reactions and therapeutic failures in revolving door patients with psychiatric illnesses: focus on the CYP2D6 isoenzymes

  2016cites this paper
• Computational predictions of the site of metabolism of cytochrome P450 2D6 substrates: comparative analysis, molecular docking, bioactivation and toxicological implications

  2015cites this paper
• Contributions of Ionic Interactions and Protein Dynamics to Cytochrome P450 2D6 (CYP2D6) Substrate and Inhibitor Binding*

  2015cites this paper
• Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer

  2015cites this paper
• Association of Cytochrome P450 with Cancer Induced by Betel Quid (BQ): A Review

  2015cites this paper
• Efeitos da participação de esteroides-like provenientes da poluição atmosférica no epitélio das vias aéreas em camundongos machos e fêmeas

  2014cites this paper
• Variability in metabolism of imipramine and desipramine using urinary excretion data.

  2014cites this paper
• Towards the clinical implementation of pharmacogenetics in bipolar disorder

  2014cites this paper
• The influence of the environment on the development of thyroid tumors: a new appraisal.

  2014cites this paper
• Chapter 4 – Drug Metabolism and Pharmacogenetics

  2013cites this paper
• Pharmacogenetics and Pharmacogenomics

  2013cites this paper
• Polymorphisms in the Human Cytochrome P450 and Arylamine N-Acetyltransferase: Susceptibility to Head and Neck Cancers

  2013cites this paper
• Modeling Human Cytochrome P450 2D6 Metabolism and Drug-Drug Interaction by a Novel Panel of Knockout and Humanized Mouse Lines

  2012cites this paper
• Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance

  2012cites this paper
• Genetic variants of CYP2D6 gene and cancer risk: a HuGE systematic review and meta-analysis.

  2012cites this paper
• Crystal Structure of Human Cytochrome P450 2D6 with Prinomastat Bound*

  2012cites this paper
• Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance.

  2012cites this paper
• Antipsychotic-Related QTc Prolongation, Torsade de Pointes and Sudden Death

  2012cites this paper
• Allele and Genotype Frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese Populations

  2012cites this paper
• Perfil genético de suscetibilidade ao desenvolvimento de carcinoma medular de tireoide

  2012cites this paper
• Genetic Variants of CYP 2 D 6 Gene and Cancer Risk : A HuGE Systematic Review and Meta-analysis

  2012cites this paper
• Clinical approach to the treatment of painful diabetic neuropathy

  2011cites this paper
• Automated Luminescence-Based Cytochrome P450 Profiling Using a Simple, Elegant Robotic Platform

  2011cites this paper
• Diagnosis and Treatment of Pain in Small-fiber Neuropathy

  2011cites this paper
• CYP2D6 in the Metabolism of Opioids for Mild to Moderate Pain

  2011cites this paper
• Opioid Guidelines Pharmacology of Opioids in the Treatment of Chronic Pain Syndromes

  2011cites this paper
• Pharmacology of opioids in the treatment of chronic pain syndromes.

  2011cites this paper
• The utility of semi-automating multiplexed assays for ADME/Tox applications.

  2011cites this paper
• Mechanisms of Drug Interactions I: Absorption, Metabolism, and Excretion

  2011cites this paper
• CYP2D6*4 polymorphisms and breast cancer risk

  2010cites this paper
• Pharmacogenetics and Pharmacogenomics

  2010cites this paper
• Probing Small‐Molecule Binding to Cytochrome P450 2D6 and 2C9: An In Silico Protocol for Generating Toxicity Alerts

  2010cites this paper
• Pharmacogenomics: a systems approach

  2010cites this paper
• Sample Size Analysis for Pharmacogenetic Studies

  2010cites this paper
• Pharmacokinetic drug interactions of synthetic opiate analgesics.

  2009cites this paper
• Pharmacokinetic / pharmacodynamic impact of genetic polymorphism of drug metabolizing enzymes

  2009cites this paper
• PHARMACOGENETICS AND PHARMACOGENOMICS

  2009cites this paper
• Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6‐drug interactions

  2008cites this paper
• Pharmacophoric Fingerprint Method (TOPP) for 3D-QSAR Modeling: Application to CYP2D6 Metabolic Stability

  2007cites this paper
• Farmacogenómica y sus aplicaciones clínicas

  2007cites this paper
• Valid comparisons of antifibrinolytic agents used in cardiac surgery.

  2007cites this paper
• Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions?

  2007cites this paper
• Polymorphism of selected enzymes involved in detoxification and biotransformation in relation to lung cancer.

  2007cites this paper
• Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group

  2007cites this paper
• the Functional Genomics and Translational Biology Interdisciplinary Working Association Council on Epidemiology and Prevention, the Stroke Council, and Cardiovascular Disease: A Scientific Statement From the American Heart Relevance of Genetics and Genomics for Prevention and Treatment of

  2007cites this paper
• Pharmacogenetic studies of antidepressant response: how far from the clinic?

  2007cites this paper
• Pharmacogenetics: using DNA to optimize drug therapy.

  2007cites this paper
• Bioactivation of Selective Estrogen Receptor Modulators (SERMs).

  2006cites this paper
• Variability in response to cardiovascular drugs.

  2006cites this paper
• Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications.

  2006cites this paper
• Pharmacogenetics and pharmacogenomics: development, science, and translation.

  2006cites this paper
• Pharmacogenetics, Race, and Psychiatry: Prospects and Challenges

  2006cites this paper
• Cytochrome P-450 2D6 and 2C19 polymorphisms and length of hospitalization in psychiatry.

  2006cites this paper
• Insights into drug metabolism from modelling studies of cytochrome P450-drug interactions.

  2006cites this paper
• Recombinant Production of Human Microsomal Cytochrome P450 2D6 in the Methylotrophic Yeast Pichia pastoris

  2005cites this paper
• Mechanisms of Drug Interactions I

  2005cites this paper
• Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo-possible involvement of different mechanisms.

  2005cites this paper
• MagSNiPer: a new single nucleotide polymorphism typing method based on single base extension, magnetic separation, and chemiluminescence.

  2005cites this paper
• Prediction of binding modes for ligands in the cytochromes P450 and other heme‐containing proteins

  2005cites this paper
• Frequency distribution of dextromethorphan O-demethylation in a Greek population.

  2005cites this paper
• Progress in cytochrome P450 active site modeling.

  2005cites this paper
• CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis

  2005cites this paper
• Pharmacogenomics: Bench to bedside.

  2005cites this paper
• Effect of sulfur dioxide inhalation on CYP1A1 and CYP1A2 in rat liver and lung.

  2005cites this paper
• [Pharmacogenomics: the quest for individualized therapy].

  2004cites this paper
• Altered Distribution of the Debrisoquine Oxidative Phenotypes in Children with Type 1 Diabetes mellitus

  2004cites this paper
• Drug Metabolism In Preclinical Development

  2004cites this paper
• Disposition of 1,2,3,4,-tetrahydroisoquinoline in the brain of male Wistar and Dark Agouti rats.

  2004cites this paper
• Pharmacogenomics: bench to bedside

  2004cites this paper
• No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline

  2004cites this paper
• Polymorphic Cytochrome P450 2D6: Humanized Mouse Model and Endogenous Substrates

  2004influential citation
• Controlled-release oxycodone.

  2004cites this paper
• Monoamine Oxidase Inhibitors and Tricyclic Antidepressants

  2004cites this paper
• Controlled-Release Oxycodone: It’s worth considering when treating around-the-clock pain.

  2004cites this paper
• Movement Disorders Induced by Selective Serotonin Reuptake Inhibitors and Other Antidepressants

  2004cites this paper
• Pharmacogenomics in breast cancer: current trends and future directions.

  2004cites this paper
• Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms

  2004cites this paper
• In silico methods for predicting ligand binding determinants of cytochromes P450.

  2004cites this paper
• SNPs in cancer research and treatment

  2004cites this paper
• A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment.

  2003cites this paper
• CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.

  2003cites this paper
• CYP2D6 Polymorphism and Tardive Dyskinesia in Schizophrenic Patients

  2003cites this paper
• Inheritance and drug response.

  2003cites this paper
• The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.

  2003cites this paper
• The Role of Pharmacogenetics in Management of Cardiovascular Disease

  2003cites this paper
• CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.

  2003cites this paper
• Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients

  2003cites this paper
• Influence of genetic factors on drug treatment efficacy and safety in cardiovascular diseases

  2003cites this paper
• Comparative molecular field analysis and QSAR on substrates binding to cytochrome p450 2D6.

  2003cites this paper
• [Basic elements of ethnopsychopharmacology].

  2003cites this paper
• Summary of information on human CYP enzymes: human P450 metabolism data

  2002cites this paper
• Dopamine in the CNS II

  2002cites this paper
• Candidate gene approach for pharmacogenetic studies.

  2002cites this paper